Akron CEO Zylberberg interviewed for the Innate Killer Summit 2018

The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as the catalyst to ensure successful clinical and commercial translation of Natural Killer (NK) cell immunotherapies. Leading up to the March 2018 event in San Diego, CA, Akron Biotechnology CEO Claudia Zylberberg, Ph.D. shared some key issues and questions arising in the NK therapy

FDA approves first gene therapy for hereditary disease — Spark Therapeutics’ Luxturna

On December 19, 2017, the US FDA approved a new gene therapy to treat children and adults with a genetic condition that often results in blindness. Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl) is a one-time gene therapy product that treats biallelic RPE65 mutation-associated retinal dystrophy, an inherited retinal disease that frequently progresses to complete blindness. Approval

Expanded genetic code with non-natural DNA rewrites life as we know it

Biological organisms use DNA to encode heritable information with just four nucleotide bases: adenine (A), thymine (T), cytosine (C), and guanine (G). These bases make up different three-letter codon sequences that produce 20 amino acids that make up proteins. Scientists have now tinkered with that standard genetic alphabet, opening up new possibilities for semi-artificial life.